

Patient Information				
Last Name: _____				
First Name: _____ MI: _____ Sex: ☐ M ☐ F				
DOB (mm/dd/yyyy): _____ SSN: _____				
Parent/Guardian (if applicable): _____ (REQUIRED if patient is <18 years old at time of sample collection)				
Address: _____ City: _____				
State: _____ Zip: _____ Phone: _____				
ICD-10 Diagnosis Code(s)				
Primary ICD-10 Code (REQUIRED)	Additional ICD-10 Code(s) (OPTIONAL)			
1	2	3	4	5
Billing Information				
BILL: ☐ Insurance* ☐ Laboratory ☐ Patient/Self-Pay ☐ Provider Account *Please provide details below <u>AND</u> attach a front/back copy of insurance card(s).				
Insurance Carrier: _____ Policy #: _____				
Provider/Account Information				
Account Name/Address: _____				
Phone: _____ Fax: _____				
Ordering Provider Selection & Signature (REQUIRED)				
Clearly select the ordering provider from list below (circle or ✓). If provider is not listed, please provide their FULL NAME AND NPI:				
Provider: _____ NPI: _____ I certify the ordered test(s) is/are reasonable and medically necessary for the diagnosis, care, and/or treatment of this patient's condition as documented in the medical record. If this patient is <18 years old at the time of testing, the parent/guardian has been informed that they will be responsible for any costs associated with testing. *Informed consent for genetic testing: I have read and understand the genetic consent requirement on page two and acknowledge I have obtained consent from my patient.				
Signature: _____				
Name: _____ Date: _____				
Sample Collection Information				
Date (mm/dd/yyyy): _____ Time: _____ ☐ AM ☐ PM				
Patient ID: _____ Sender Sample ID: _____				
MEDICARE ONLY - HOSPITAL STATUS WHEN SAMPLE WAS COLLECTED: ☐ Hospital Inpatient ☐ Hospital Outpatient ☐ Non-Hospital Patient				
Laboratory/Other Name/Address: _____				
Phone: _____ Fax: _____				
Results: ☐ Mail ☐ Fax ☐ No Results to Lab				

IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn's disease; IV: Intravenous; SC: Subcutaneous; TPMT: thiopurine methyltransferase; HCV: Hepatitis C; MASH: Metabolic dysfunction-associated steatohepatitis; NASH: Non-alcoholic steatohepatitis

Select Test(s) To Be Performed						
— Liver —						
☐ MASH PreciS™ (#4105) Stages liver fibrosis to identify treatment-eligible MASH patients ≥18 years old and includes an Enhanced Liver Fibrosis (ELF*) risk score.						
☐ FIBROSpect® HCV (#4000) Assessment of liver fibrosis severity for HCV patients.						
☐ FIBROSpect® NASH (#4100) Differentiate F0-F2 from F3-F4 liver fibrosis for NASH Patients.						
— Therapeutic Drug Monitoring —						
☐ Anser® IFX (#3150) Simultaneously measures infliximab (IFX) and antibody-to-IFX (ATI) levels. Select biologic and route of administration (optional): ☐ ZYMFENTRA® SC (IFX-dyyb) ☐ INFLECTRA® IV (IFX-dyyb) ☐ AVSOLA® IV (IFX-axxq) ☐ REMICADE® IV (infliximab) ☐ RENFLEXIS® IV (IFX-abda) ☐ Other: _____						
☐ Anser® ADA (#3170) Simultaneously measures adalimumab (ADA) and antibody-to-ADA (ATA) levels. Select biologic (optional): ☐ HUMIRA® (adalimumab) ☐ Other: _____						
☐ Anser® VDZ (#3180) Simultaneously measures vedolizumab (VDZ) and antibody-to-VDZ (ATV) levels.						
☐ Anser® UST (#3190) Simultaneously measures ustekinumab (UST) and antibody-to-UST (ATU) levels. Select biologic (optional): ☐ STELARA® (ustekinumab) ☐ Other: _____						
☐ Anser® RZB (#3140) Simultaneously measures risankizumab (RZB) and antibody-to-RZB (ATR) levels.						
Anser Testing - Biologic Dosing Data (optional)						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th>Date of Last Dose (mm/dd/yyyy)</th> <th>Current Dose</th> <th>Current Interval</th> </tr> <tr> <td>_____</td> <td> ☐ mg ☐ mg/kg </td> <td> ☐ days ☐ weeks </td> </tr> </table>	Date of Last Dose (mm/dd/yyyy)	Current Dose	Current Interval	_____	☐ mg ☐ mg/kg	☐ days ☐ weeks
Date of Last Dose (mm/dd/yyyy)	Current Dose	Current Interval				
_____	☐ mg ☐ mg/kg	☐ days ☐ weeks				
☐ RiskImmune®† (#3600) Assesses genetic predisposition to immunogenicity to anti-TNF therapy.						
☐ TPMT Genetics† (#3300) Aids in individualized thiopurine dosing based on patient TPMT genotype.						
☐ TPMT Enzyme (#3320) Phenotyping test that aids in individualized thiopurine dosing.						
☐ Thiopurine Metabolites (#3200) Aids in optimization of thiopurine dosing to achieve clinical response.						
Current Thiopurine Dosing (optional)						
☐ 6-MP _____ mg/day ☐ AZA _____ mg/day ☐ Other _____ mg/day						
— Celiac —						
☐ Celiac PLUS† (#6360) Includes Celiac Genetics and Celiac Serology.						
☐ ONLY Celiac Genetics† (#6260) Genetic profile to aid diagnosis of celiac disease.						
☐ ONLY Celiac Serology (#1155) Antibody profile to aid diagnosis of celiac disease. — ONLY the following designated component(s) of Celiac Serology —						
☐ Anti-Human Tissue Transglutaminase IgA (tTG IgA) (#1405) ☐ Anti-Endomysial IgA (EMA IgA) (#1505) ☐ Total serum IgA (#1605) ☐ DGP IgA (#1255) ☐ DGP IgG (#1355)						
Miscellaneous Testing						
☐ Other Prometheus Testing†: _____ †Acknowledgment of informed consent required if genetic testing is indicated above. Refer to page two or contact Client Services to confirm specimen requirements.						
— Specimen collection requirements on page 2 —						
*Acknowledgment of informed consent for genetic testing required. *Failure to provide the required data, at the time of sample collection, may result in reporting delay/cancellation.						

Specimen Collection and Handling Procedures					
Test Ordered	Turnaround Time ^a	Shipping Conditions	Specimen Type and Volume	Specimen Collection Tube	Specimen Stability
Anser[®] ADA, IFX, RZB, UST, VDZ	3 days	Ambient or Cold Pack	2.0 mL Serum (0.5 mL for Peds)	Serum Separator Tube or Red-Top Tube	Room Temp: 14 days Refrigerated: 14 days
Celiac PLUS[†]	4 days	Ambient or Cold Pack	2.0 mL Serum AND 2.0 mL Whole Blood	Serum Separator Tube or Red-Top Tube AND EDTA/Lavender-Top Tube	Room Temp: 7 days Refrigerated: 30 days
Celiac Genetics[†]	4 days	Ambient or Cold Pack	2.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room Temp: 7 days Refrigerated: 30 days
Celiac Serology (including all components)	4 days	Ambient or Cold Pack	2.0 mL Serum (0.5 mL for Peds)	Serum Separator Tube or Red-Top Tube	Room Temp: 7 days Refrigerated: 30 days
FIBRO Spect[®] HCV, NASH	7 days	Ambient or Cold Pack	2.0 mL Serum (0.5 mL for Peds)	Serum Separator Tube or Red-Top Tube	Room Temp: 7 days Refrigerated: 30 days
IBD Precis[®]	4 days	Ambient or Cold Pack	2.0 mL Serum (0.5 mL for Peds)	Serum Separator Tube	Room Temp: 7 days Refrigerated: 14 days
MASH Precis^{TM†}	3-5 days	Cold Pack Required	2.0 mL Serum	Serum Separator Tube	Refrigerated: 3 days
		Cold Pack Preferred	2.0 mL Serum Supernatant Post Clotting and Centrifugation	Polypropylene Transfer Tube	Room Temp: 2 days Refrigerated: 7 days
Riskimmune^{®†}	4 days	Ambient or Cold Pack	2.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room Temp: 10 days Refrigerated: 30 days
Thiopurine Metabolites	3 days	Cold Pack Preferred	5.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room Temp: 1 day Refrigerated: 8 days
TPMT Enzyme	3 days	Cold Pack Preferred	5.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room Temp: 1 day Refrigerated: 8 days
TPMT Genetics[†]	4 days	Ambient or Cold Pack	2.0 mL Whole Blood	EDTA/Lavender-Top Tube	Room Temp: 10 days Refrigerated: 30 days

^aBusiness days from date of receipt.

[†] Acknowledgment of informed consent for genetic testing required.

[‡] Withhold multivitamins or dietary supplements containing biotin, 8 hours (standard dose) to 72 hours (mega-dose), prior to specimen collection.

Specimens should be labeled with 2 identifiers and date of collection. Examples of acceptable identifiers include, but are not limited to: patient name, date of birth, hospital number, accession number, or unique random number. Unlabeled specimens will not be accepted for testing. Whole blood and samples in a serum-separator tube should not be frozen.
SHIPPING INSTRUCTIONS: Prometheus has an agreement with FedEx[®] for express overnight delivery within the United States and Canada. Please call FedEx at 1-800-GoFedEx (463-3339) to schedule a pickup. FedEx will pick up your specimens and ship them to Prometheus Laboratories Inc. in San Diego at no expense to you. Prometheus will provide specimen transportation kits upon request. **NOTE:** Multiple specimens may be shipped in a single transportation kit. **For more information, call Client Services at 888-423-5227, or go to prometheuslabs.com.**

ACKNOWLEDGMENT OF INFORMED CONSENT FOR GENETIC TESTING

I warrant that this test was ordered and that I have obtained the appropriate prior written consent. This written consent was signed by the person who is the subject of the test (or if that person lacks capacity to consent, signed by the person authorized to consent for that person) and includes the following (unless certain that the following information is not required by the state in which I practice):

1. The purpose of this test is to determine if the patient may have a variant in the gene(s) being tested, which has been found to be associated with this condition.
2. This test will only test for this specific condition and will not detect ALL possible variants within this gene, nor will it detect variants in other genes.
3. Prior to my signature of the written consent, a qualified healthcare professional discussed with the patient the genetic test ordered and described the steps involved in the test, the constraints of the procedure, and its accuracy.
4. My patient was advised by a qualified healthcare professional of the risks and benefits of genetic testing, and advised of the significance of a positive and negative result.
5. The patient understands that a positive test result is an indication that the patient may be predisposed to, or have, the condition listed.
6. The patient understands that the test may fail, that the results may be non-informative or not predictive for his/her case, and that the test may reveal information that is unrelated to their intended purpose.
7. No unauthorized test is performed on specimens.
8. NY-state specimens will be destroyed within 60 days after collection when no longer required for clinical purposes.
9. The informed consent does not authorize the use or release of any other identified medical information unrelated to this genetic test
10. The patient understood that he/she could see professional genetic counseling prior to undergoing the testing procedure, and received written information identifying a genetic counselor or medical geneticist by his/her treating provider.

Prometheus Client Services | Main: 888-423-5227 | Fax: 877-816-4019 | 6:00 am - 4:30 pm Pacific Time

Prometheus tests are laboratory-developed tests that were developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and are performed exclusively in our high complexity CLIA certified and College of American Pathologists accredited clinical laboratory. As laboratory developed tests, they have not been cleared or approved by the US FDA. The tests may be covered by one or more US pending or issued patents - see prometheuslabs.com/patents. Prometheus, Anser, FIBRO Spect, IBD Precis, MASH Precis and Riskimmune are trademarks or registered trademarks of Prometheus Laboratories Inc, San Diego, California. All other trademarks or service marks are the property of their respective owners. ©2026 Prometheus Laboratories Inc. All rights reserved.